Advanced searches left 3/3

Cardiac Amyloidosis - Crossref

Summarized by Plex Scholar
Last Updated: 05 September 2022

* If you want to update the article please login/register

Myocardial Scintigraphy in Diagnosing Cardiac Transthyretin Amyloidosis

A minimally invasive method that can distinguish between transthyretin amyloidosis and light-chain amyloidosis is a Myocardial scintigraphy with technetium-99 million pyrophosphate. We present a situation in which we helped identify the amyloidosis type in a 74-year-old man with heart disease and multiple previous admissions for acute decompensated heart failure in a 74-year-old man. Patient presenting with increasing abdominal girth and bilateral lower extremity edema. His acute decompensated heart disease with cardiorenal syndrome and his decompensated cirrhosis were aided by a guideline-directed medical therapy. A presumptive diagnosis of ATTR cardiomyopathy had been made two years ago, primarily cardiac involvement, unremarkable serum protein electrophoresis result, and unusually high free u03b/u03b ratio of 2. 24. This case shows that technonetium-99 million pyrophosphate scintigraphy can help diagnose ATTR cardiomyopathy and identifying patients who may benefit from disease-modifying therapy.

Source link: https://doi.org/10.14503/thij-20-7379


Cardiac AL amyloidosis presenting as recurrent dyspnoea in a patient with cancer: an important clinical clue to an early diagnosis

Cardiac amyloidosis is difficult to detect due to its non-specific clinical signs early in the disease process. We chronicle the case of a patient who complained of dyspnoea, abdominal distension, and leg swelling in a patient. Multiple hospital readmissions for dyspnoea occurred over a year before the official diagnosis of California. Our example shows the importance of having a high rate of clinical suspicion for an early diagnosis of CA.

Source link: https://doi.org/10.1136/bcr-2021-245969


Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma

We wanted to explore the prevalence of secondary cardiac amyloidosis in MM patients with t and to determine its effect on survival results. The correlations between cardiac amyloidosis and clinical and biological parameters were scientifically reviewed, and the effects of concomitant of cardiac amyloidosis on survival and prognosis of MM patients with t were also investigated. Patients with cardiac amyloidosis had elevated NT-proBNP and elevated hs-cTnT, while patients without cardiac amyloidosis had a greater incidence of hemoglobin 80 g/L, and bone destruction. In addition, patients with NT-proBNP > 1,800 pg/ml or hs-cTnT >226740 pg/ml or light chain only had a significantly shorter mean OS compared to patients with lower NT-proBNP, hs-cTnT, or another M-protein isotype. Conclusions The t MM patients with coexisting cardiac amyloidosis may be a distinct clinical entity with no cure.

Source link: https://doi.org/10.3389/fcvm.2022.994384


Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Background: In cardiac amyloidosis, the incidence of thromboembolic signs and atrial fibrillation is elevated in transthyretin amyloidosis relative to immunoglobulin light chain amyloidosis is higher than in cardiac fibrillation. We therefore conclude that transthyretin cardiac amyloidosis patients have poorer atrial function. Methods: Echocardiographic strain analysis was done in cardiac amyloidosis patients in our Amyloidosis Expert Center using speckle tracking. Amyloidosis patients' results were reviewed, revealing 53 cardiac amyloidosis patients. Patients with Transthyretin cardiac amyloidosis were older and had more left ventricular hypertrophy than immunoglobulin light chain cardiac amyloidosis patients. Conclusions: Transthyretin cardiac amyloidosis patients had reduced left atrial reservoir function when compared to immunoglobulin light chain cardiac amyloidosis patients, although the left atrial geometry was similar. Heart disease prevalence and prognosis in transthyretin cardiac amyloidosis are both important and prognosis, according to more research is needed to determine the effect of reduced left atrial dysfunction in transthyretin cardiac amyloidosis on atrial fibrillation burden and prognosis.

Source link: https://doi.org/10.3390/biomedicines10081768


A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study

obstructive epicardial coronary artery disease sufferers have been diagnosed with anginal symptoms and signs of ischemia in some patients with cardiac transthyretin amyloidosis without obstructive epicardial coronary artery disease. And in the absence of epicardial CAD, few studies found that coronary microvascular dysfunction was extremely common in patients with cardiac amyloidosis. After 24 months of treatment, the aim of this study is to document coronary microvascular disease and go further with the evaluation of Tafamidis' effect on microvascular dysfunction. Adult patients with confirmed ATTR cardiomyopathy seen in three major referral centers' nuclear medicine departments and treated with Tafamidis will be included. The primary outcome of this research will be the difference between stress and rest myocardial blood flow and flow reserve between baseline and 24 months after treatment. The study has been approved by the following bodies: The Orleans Hospital Research Committee and the Sud-Mediterrane IV Regional Ethics Committee.

Source link: https://doi.org/10.3389/fmed.2022.978293


Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma

Cardiac amyloidosis is a common form of heart injury caused by MM and is associated with poor prognosis. In MM patients, this was a prospective cohort study with the aim of determining the clinical relevance of extracellular volume fraction based on cardiovascular magnetic resonance T1 mapping for cardiac amyloidosis and cardiac dysfunction. The CA group's basal ECV was significantly higher than that of the non-CA group despite being largely younger than that of the non-CA group. According to a new analysis, basal ECV in the heart failure group was significantly higher than that of the nonheart failure group.

Source link: https://doi.org/10.1155/2022/3094933


Transthyretin cardiac amyloidosis

Transthyretin cardiac amyloidosis is a common cause of heart disease and mortality around the world. Amyloid fibril formation is a result of an age-related lack of homoeostatic functions in wild-type ATTR amyloidosis or destabilizing mutations in variant ATTR amyloidosis. Longitudinal large-scale studies in the United States reveal an incidence of cardiac amyloidosis in the current age of 17 per 100 000, which has almost due to misdiagnosis and underestimated. Patients hospitalized for HF with preserved ejection fraction can be identified in up to 15% of patients with elevated ejection fractions, with both ATTRwt and ATTRv amyloidosis. With u2018boneu2019 tracers and biochemical analyses, it can be possible to distinguish ATTR from light chain amyloidosis.

Source link: https://doi.org/10.1093/cvr/cvac119


Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis

Abstract Aims Aortic stenosis and cardiac amyloidosis commonly coexist, but diagnostic diagnosis of CA in AS patients remains a mystery. We want to establish the echocardiographic parameters that could aid in the detection of CA in AS patients. Out of the 1449 patients included, 160 patients had both ASTMu2013CA, while the remaining 1289 patients had AS-only, with ASu2013CA. Myocardial contraction fraction SMD: u22120. 69, 95% CI: u22122. 73, 95 percent CI: u22120. 07 to u22120. 04, P = 0. 0515, SMD: u22120. 06 to u22120. 37, 95% CI: u22120. 70 to u22120. 36, 0. 8 percent CI: u22121. 61 to u22120. Conclusions A study based on echocardiography demonstrated a promising result in finding CA in patients with AS.

Source link: https://doi.org/10.1093/ehjci/jeac146

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions